Elizabeth Weesner et al. 2022. Injection Site Reaction to Extended-Release Buprenorphine (Sublocade®) for Opioid Use Disorder Fourteen Days after Administration. Kansas Journal of Medicine. 15, 2 (Aug. 2022), 302–304. DOI:https://doi.org/10.17161/kjm.vol15.17931.